CytoDyn Inc.
CytoDyn is a clinical-stage biotechnology company developing leronlimab, a humanized monoclonal antibody that targets the CCR5 receptor. Its development work focuses on potential treatments for solid-tumor cancers, including relapsed or refractory metastatic colorectal cancer and metastatic triple-negative breast cancer. CytoDyn is conducting the Phase 2 CLOVER study of leronlimab with TAS-102 and bevacizumab for metastatic colorectal cancer, and it has an Expanded Access Program for eligible patients with triple-negative breast cancer. It is also pursuing preclinical and clinical development work in glioblastoma and a joint effort to develop longer-acting molecules. CytoDyn’s business centers on clinical development and potential commercialization of leronlimab. It seeks to fund development through traditional fundraising and non-dilutive opportunities such as license agreements and co-development or strategic partnerships. CytoDyn is headquartered in Vancouver, Washington.
No SEC Form 4 filings for $CYDY in the last 30 days.
See all $CYDY insider activity →CytoDyn (CYDY) received a $5M investment from an anonymous private investor to support its leronlimab clinical development programs, according to the company's announcement.
CytoDyn (CYDY) presented updated Phase 2 data for leronlimab in metastatic colorectal cancer at ESMO 2026, showing consistent tumor CCR5 expression and early ctDNA reductions. The findings include safety and biomarker data, according to the company.
CytoDyn reported early CLOVER study data, showing an average 93% ctDNA decrease in 12 patients. The company plans to present updated data at upcoming medical conferences. CytoDyn also named Robert Hoffman as CEO and expects cash to fund operations into mid-2027. The company is pursuing regulatory paths for leronlimab, including Fast Track and Breakthrough Therapy designations, and is exploring additional cancer studies. CytoDyn had $18.3 million in cash as of August 31, 2024.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CYDY (CytoDyn Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent CYDY coverage spans financial news, corporate actions and technology.
The modest raise provides short‑term funding but is unlikely to move the stock significantly.
Positive early biomarker signals could boost investor sentiment.
Positive early trial results and leadership change may boost investor confidence.
Leadership transition may affect strategic direction and investor sentiment.
Leadership transition may create short‑term volatility as investors reassess execution outlook.
AlphAI scores every news story that mentions CYDY with an AI model for sentiment and relevance, and aggregates insider trades from CytoDyn Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CytoDyn (CYDY) received a $5M investment from an anonymous private investor to support its leronlimab clinical development programs, according to the company's announcement.
CytoDyn (CYDY) presented updated Phase 2 data for leronlimab in metastatic colorectal cancer at ESMO 2026, showing consistent tumor CCR5 expression and early ctDNA reductions. The findings include safety and biomarker data, according to the company.
CytoDyn reported early CLOVER study data, showing an average 93% ctDNA decrease in 12 patients. The company plans to present updated data at upcoming medical conferences. CytoDyn also named Robert Hoffman as CEO and expects cash to fund operations into mid-2027. The company is pursuing regulatory paths for leronlimab, including Fast Track and Breakthrough Therapy designations, and is exploring additional cancer studies. CytoDyn had $18.3 million in cash as of August 31, 2024.
Robert E. Hoffman, 60, has been named CEO of CytoDyn, replacing Jacob P. Lalezari, who will now lead research and translational sciences. Hoffman has held CFO/CEO roles at other biotech firms and serves on boards. He joined CytoDyn as CFO in May 2025.
CytoDyn Inc. (CYDY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, October 19, 2026 -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage on
CytoDyn Inc. (CYDY) will host an investor webcast on October 19, 2026, to discuss clinical and financial updates, including early tumor-DNA observations from its CLOVER cancer study. The event will feature CytoDyn executives and a Natera representative, focusing on their strategic collaboration. The webcast will be available for replay for 30 days.
CytoDyn Inc. reported a net loss of $19.9M for Q3 2026, widening from a $5.5M loss in the prior-year quarter, with no revenue disclosed. Diluted EPS was $(0.01). The company is focusing on leronlimab's clinical development in oncology, increasing R&D spending, and seeking partnerships for financing.
CytoDyn Inc. reported a net loss of $42.7M for fiscal 2026, a significant decline from a $3.7M net income in 2025. The company's cash reserves stood at $11.9M, with working capital and accumulated deficits raising concerns about its ability to continue operations. CytoDyn cited clinical development progress and strategic partnerships as key highlights.
We have a $2.75 Price Target on CytoDyn ( CYDY ) in the Next 6 to 12 Months. The stock's current price is around $0.32. CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting the CCR5 receptor, with applications in HIV, ...
